Naperville, IL -- (ReleaseWire) -- 01/15/2014 --Reportstack, provider of premium market research reports announces the addition of China Nuokang Bio-Pharmaceutical Inc. - Strategic SWOT Analysis Review market report to its offering
China Nuokang Bio-Pharmaceutical Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the companys key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy summarization of the companys business strategy.
- SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities A list of key manufacturing facilities of the company.

Highlights

China Nuokang Bio-Pharmaceutical Inc. (China Nuokang) is a biopharmaceutical company. The company develops, manufactures and markets hematological and cardiovascular products. Its products include Baquting and Aiduo. China Nuokangs Baquting is a hemocoagulase product that holds proteolytic enzyme batroxobin, which promotes the blood coagulation process. The companys Aiduo is an injectible coronary vasodilator, which is used as a diagnostic agent in connection with myocardial perfusion imaging. Its Aiduo is used in the treatment of coronary arterial diseases. The company conducts healthcare and biotechnological research. It holds six patents.

China Nuokang Bio-Pharmaceutical Inc. Key Recent Developments

Nov 25, 2012: China Nuokang Bio-Pharma Reports Revenue Of RMB75.4m In Q3 2012
Aug 22, 2012: China Nuokang Bio-Pharma Reports Revenue Of RMB72.9m In Q2 2012
Jun 15, 2012: China Nuokang Bio-Pharma Appoints Felix Chungfai Wong As CFO
May 23, 2012: China Nuokang Bio-Pharmaceutical Reports Revenue Of RMB60.3m In Q1 2012
Mar 14, 2012: China Nuokang Bio-Pharmaceutical Reports Revenue Of RMB57m In Q4 2011

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/148745/china-nuokang-bio-pharmaceutical-inc-strategic-swot-analysis-review.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###